Tamsulosin Sr Pellets 0.20% W/W & 0.13% W/W Pellets

What are Tamsulosin Sr Pellets 0.20% W/W & 0.13% W/W Pellets?

Tamsulosin Sr Pellets 0.20% W/W & 0.13% W/W Pellets are pharmaceutical pellet formulations identified by two stated tamsulosin drug-loading levels. Tamsulosin is an alpha-1 adrenergic receptor blocker used in specific finished medicines to relieve urinary symptoms associated with benign prostatic hyperplasia. The exact release characteristics, formulation composition and intended manufacturing applications should be confirmed against the applicable technical documentation.

Uses / Applications

These pellets may be evaluated for pharmaceutical formulation and further processing, subject to confirmation of their specifications and intended use.

Potential applications include:

• Use as an intermediate in the manufacture of an appropriate oral dosage form, where supported by the product documentation.

• Incorporation into a validated formulation requiring tamsulosin.

• Development of a finished medicinal product with a defined tamsulosin dose and release profile, subject to formulation and quality requirements.

Therapeutic context: Tamsulosin-containing medicines are used to relieve lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). This is a therapeutic use of the finished medicine and does not establish that the supplied pellets are suitable for direct administration.

6. Benefits

Potential formulation-related considerations include:

• Two stated drug-loading levels: 0.20% w/w and 0.13% w/w.

• Identifiable active ingredient: Tamsulosin is the stated active ingredient.

• Sustained-release designation: SR is included in the supplied product name; the release performance must be verified.

• Formulation development: The material may be evaluated for use in an appropriate pharmaceutical manufacturing process.

Content uniformity, particle size, release performance, stability and compatibility with other ingredients must be established through product-specific documentation and appropriate testing.

7. Side Effects

The supplied product is described as pharmaceutical pellets, and its suitability for direct patient administration has not been established.

Patient-level adverse effects cannot be determined from the pellet dosage form alone. Safety depends on the final formulation, dose, route of administration and approved product information.

Tamsulosin-containing medicines may cause dizziness, light-headedness, postural hypotension and ejaculation-related disorders. Less common but important risks include fainting and hypersensitivity reactions. Intraoperative floppy iris syndrome has also been reported in patients undergoing cataract or glaucoma surgery.

These risks relate to finished tamsulosin medicines. Refer to the approved product information for the specific medicinal product.

8. How Does It Work?

Formulation mechanism: The product name identifies the material as sustained-release (SR) pellets. However, the specific release-controlling technology, excipients and release specifications have not been supplied. These characteristics should be verified through the technical documentation.

Pharmacological mechanism: Tamsulosin selectively blocks alpha-1 adrenergic receptors, particularly those involved in smooth-muscle tone in the prostate and bladder neck. This helps relax these tissues and improve urinary flow in patients with appropriate indications.

9. Dosage Guidelines / Processing Instructions

For pharmaceutical processing, the required incorporation level depends on the verified drug loading, target dosage strength, formulation design and validated manufacturing process.

• Confirm whether the 0.20% w/w and 0.13% w/w specifications refer to separate pellet grades or other product variants.

• Verify the assay basis and applicable technical specifications before calculating quantities.

• Assess compatibility with other formulation ingredients.

• Evaluate finished-product content uniformity and release performance using appropriate quality-control methods.

• Do not assume the pellets can be swallowed directly, crushed, chewed or incorporated into a dosage form without product-specific instructions.

No processing quantities, temperatures, mixing times or manufacturing parameters are specified because supporting technical information has not been supplied.

For patient administration, follow the approved information for the finished medicinal product and the recommendation of a qualified healthcare professional.

10. When Not to Use

The pellets should not be used in a formulation until their identity, quality and suitability for the intended process have been confirmed.

For finished medicines containing tamsulosin, contraindications may include known hypersensitivity to tamsulosin or relevant product ingredients. Additional precautions depend on the patient’s clinical condition and the approved product information.

These considerations relate to tamsulosin-containing medicinal products and should not be treated as blanket contraindications for handling a pharmaceutical intermediate.

11. Drug / Product Interactions

For pharmaceutical intermediates, compatibility with excipients and other active ingredients must be established through formulation development and technical assessment.

For finished medicines containing tamsulosin, relevant clinical interactions may include:

• Other alpha-1 adrenergic blockers: Concurrent use may increase the risk of low blood pressure.

• Antihypertensive medicines: Blood-pressure-lowering effects may require clinical assessment.

• Strong CYP3A4 inhibitors: These may increase tamsulosin exposure.

• CYP2D6 inhibitors: These may affect tamsulosin metabolism and exposure.

• Cimetidine: May increase tamsulosin concentrations in some circumstances.

The specific clinical significance depends on the finished medicine and the patient’s circumstances. These interactions should not be confused with formulation compatibility during manufacturing.

12. Safety Advice

• Handle the material according to its applicable safety data sheet and technical documentation.

• Follow the receiving manufacturer’s procedures for pharmaceutical material handling.

• Apply occupational precautions based on the documented hazards of the active ingredient and formulation components.

• Avoid unnecessary dust generation and exposure.

• Verify material identity and batch traceability before processing.

• Do not use the pellets for direct patient administration unless their intended use and suitability have been established.

13. General Instructions

• Verify the exact product name and both stated drug-loading levels.

• Confirm whether the two percentages represent separate product variants.

• Check batch identification and applicable manufacturing, expiry or retest details.

• Inspect packaging for damage or contamination.

• Review the certificate of analysis and technical data sheet when available.

• Confirm that the material meets the receiving manufacturer’s specifications.

• Follow documented processing, handling and storage instructions.

• Maintain appropriate quality-control and material traceability records.

14. Special Dietary / Lifestyle Tips

Dietary and lifestyle advice is generally not applicable to pharmaceutical pellets intended for further processing.

Any patient guidance depends on the final medicinal product and its approved instructions. Patients taking tamsulosin-containing medicines may need advice about dizziness, postural hypotension and activities requiring alertness. Such advice should be based on the relevant finished product’s prescribing information.

15. Comparison with Other Formulations

No formulation is universally superior. Selection depends on the intended application, technical specifications and validated manufacturing requirements.

16. Precautions & Warnings

• Verify the drug-loading basis for both 0.20% w/w and 0.13% w/w variants.

• Confirm the intended meaning of SR and the documented release characteristics.

• Do not assume a specific coating, particle size or release-control technology.

• Evaluate compatibility with the intended manufacturing process.

• Follow the approved technical documentation for storage and handling.

• Assess clinical safety against the approved information for the finished tamsulosin medicine.

• Do not treat the supplied drug-loading percentages as finished-product dosage strengths.

17. Can I Use It With Other Medicines or Ingredients?

Compatibility with other active ingredients and excipients cannot be established from the product name alone.

Before combining Tamsulosin SR Pellets with other materials, the receiving manufacturer should assess:

• Physical and chemical compatibility.

• Drug-loading and content-uniformity requirements.

• Effects of processing on pellet integrity.

• Release performance in the intended finished dosage form.

• Stability and other applicable quality requirements.

Clinical use of tamsulosin alongside other medicines is a separate consideration and must be evaluated against the approved prescribing information.

18. Storage

Store according to the manufacturer’s approved product specifications and technical documentation. Refer to the product packaging or applicable technical data sheet for the required storage conditions.

19. Frequently Asked Questions (FAQs)

1. What are Tamsulosin SR Pellets 0.20% W/W & 0.13% W/W Pellets?

They are a pharmaceutical pellet product identified as containing tamsulosin at two stated drug-loading levels: 0.20% w/w and 0.13% w/w.

2. What is the active ingredient?

The stated active ingredient is tamsulosin, an alpha-1 adrenergic receptor blocker used in certain medicines for urinary symptoms associated with benign prostatic hyperplasia.

3. What do 0.20% W/W and 0.13% W/W mean?

These are the drug-loading percentages supplied in the product name. The specification should confirm whether they represent separate pellet variants and define the applicable assay basis.

4. Are these sustained-release pellets?

The abbreviation “SR” indicates sustained release in the supplied name. The actual release characteristics should be verified against the product’s technical documentation.

5. Are the pellets suitable for direct administration?

Direct administration suitability has not been established. Their intended use must be confirmed through the applicable product documentation.

6. What packing options are available?

Packing details have not been provided. Packaging requirements should be confirmed with Kelar Pharmachem India for the specific supply enquiry.

7. Is a technical data sheet available?

The technical data sheet is available upon request, subject to confirmation of the applicable product documentation.

8. Can this product be sourced for pharmaceutical export?

Kelar Pharmachem India operates as a pharmaceutical sourcing and export company. Product availability, destination-market requirements, supporting documentation and supply terms should be confirmed for the specific enquiry.